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Mutations,  designed by analysis of the crystal struc- 
tures of Rous  sarcoma virus (RSV) and human  immuno- 
deficiency virus type 1 (HIV-1) protease (PR), were in- 
troduced into the substrate binding pocket of  RSV  PR. 
The mutations substitute$ nonconserved residues of 
RSV PR,  located within 10 A of the substrate, for those in 
structurally equivalent positions of HIV-1 PR. Changes 
in the activity of purified mutants were detected in  vitro 
by following  cleavage of synthetic peptides representing 
wild-type and modified RSV and HIV-1 gag and pol 
polyprotein cleavage sites. Substituting threonine for 
valine 104  (V104!l‘),  S107N,  I44V,  Q63M or deletion of resi- 
dues 61-63  produced  enzymes that were 2.5-7-fold more 
active than  the wild type RSV PR. Substituting I42D, 
M73V, and AlOOL produced enzymes  with  lower  activity, 
whereas a mutant that included both M73V and AlOOL 
was as active as wild  type. Several substitutions altered 
the specificity for substrate. These include I42D and 
I44V, which contribute to the 52 and 52’ subsites.  These 
proteins exhibited HIV-1 PR specificity for P2- or P2‘- 
modified peptide substrates  but unchanged  specificity 
with P4-, P3-, P1-, P1’-, and P3”modified substrates. 
Changes in specificity in  the 54 subsite were detected by 
deletion of residues 61-63.  These results confirm the hy- 
pothesis that the subsites of the substrate binding 
pocket of the retroviral protease are capable of acting 
independently in  the selection of substrate amino  acids. 
The retroviral protease (PR)’ is responsible for the post- 
translational  processing of the gag and pol polyprotein  precur- 
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sols of nascent  virus  particles (1). This  process,  termed  matu- 
ration,  is  necessary for the  production of infectious  virions (1). 
Loss of PR  activity  either  by the presence of inhibitors or by 
mutations  results  in  the  production f immature,  noninfectious 
particles (2-4). As a result,  PR  is a target for the design of 
antiviral  agents. 
PRs from different retroviruses efficiently recognize and 
process  sequences  present  in  their  cognategag  andpol polypro- 
teins  (5). Yet there  is  no  simple  consensus  sequence  when  one 
compares  the  sequences  known  to  be specifically and efficiently 
processed  by a particular PR. Additionally,  heterologous  activ- 
ity, that is,  activity of PR  from  one  retrovirus  on thegag and pol 
polyprotein  cleavage  sites of another  retrovirus, has been  re- 
ported  (6).  The  PRs  possess  intricately  designed  substrate  bind- 
ing  pockets that contain at least  seven  subsites  (S4-S3’)  which 
interact with 7 amino acids of the substrate (P4-P3’) (7, 8). 
Although  the  general  topologies of the  substrate  binding pock- 
ets of different  PRs  are  virtually  identical,  subtle  differences in 
structure  and  amino  acid  composition do exist (9). These are 
likely responsible for the differences in activities observed 
among the various  proteases. For instance,  the RSV PR  is 10- 
20-fold less  active  catalytically than HIV-1 PR  (1,  6). Also, the 
RSV PR is  more  stringent  in the selection of substrates  than 
HIV-1 PR (6, 9); HIV-1 PR  is  capable of specifically and   e f i -  
ciently  processing  peptides  representing  the RSV gag and pol 
polyprotein  cleavage  sites,  whereas  the  converse  is  not rue. 
We have  used  site-directed  mutagenesis  to  investigate  the 
significance of nonconserved amino acid residues of the PR 
substrate  binding  pockets.  Using  crystallographic  information 
available  for  the RSV and HIV-1 enzymes  (9),  we  identified 11 
amino  acid  residues of the RSV PR which are  within 10 A of the 
substrate  and are not  identical  in  the HIV-1 PR. These residues 
are:  Ser-38,  Ile-42,  Ile-44,  Gln-63,  His-65,  Met-73,  Ala-100, Val- 
104,  Arg-105,  Gly-106, and Ser-107.  The  residues  in  the  struc- 
turally  analogous  positions of the HIV-1 PR are Thr-26,  Asp-30, 
Val-32, Met-46,  Gly-48,  Val-56,  Leu-76,  Thr-80,  Pro-81, Val-82, 
and Asn-83, respectively. (For clarity,  amino  acids  derived  from 
HIV-1 PR will  be  placed in italics throughout the text  and  the 
one letter notation for amino acids will be used to refer to 
substitutions and mutations.) 
In a previous  report,  we  described  results  from  substitutions 
that affected the S1 and S1’  subsites of the RSV PR  substrate 
avian myeloblastosis virus; NC, nucleocapsid; IN, integrase; PheSta, 
statine derivative of phenylalanine. 
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TABLE I




14W CGCTGTTGGACTCTGGCGCCGACGACACTATTATTTCAGAGG3' KasI 
I44V TGGAGCGGACATCACTGTGATATCAGAGGAGGATTGGC3' EcoRV 
Q63M GGAGGCCGCGAACCCGATGATTCATGGGATAGGAGGGG3' N ~ ~ I ~  
H65G AGCAGATCTCTCACCTACCAAACAATG3' BstXI 
TGGGAATTCCCCCTCCTATCCCACCGATCTGGGGGTTCGCG 
GCCTCCA3' 
M73V AGGAGGGGGAATTCCCGTTCGWTCTCGTGACA3'  S f U I  
AlOOL CCCTGCTCCTCTTCCCACTAGTAGCTATGGTTAGA3' SpeI 
M73V, AlOOL Same  as above SfuVSpeI 
V104T CCCCGCAGTAGCTATGACGCGTGGGAGTATCCTAGGAA3' MluI 
S107N GC TATGGTTAGAGGGAATATTCTAGGPAGAGATTGTC3' ssp1 
N 6 P ,   P 6 Z ,  Q63M AGTGATGGAGGCCGCGCCCCTCATGATTCATGGGATAG3' BspHI 
A6143 AGTGATGGAGGCCGCGATTCATGGGATAGGAGGGGGA3' N C O I ~  
R105P, G106V CCGCAGTAGCTATGGTACCAGTGAGTATCCTAGGAAGA3' KpnI 
R105P, G106V, S107N AGCTATGGTACCAGTGAATATTCTAGGAAGAGATTGTC3' KpnVSspI 
V104T, R105P, G106V, S107N TCCCCGCAGTAGCTATGACACCGGTGAATATTCTAGG AgeIISspI 
AAGA3' 
a Mutations  are  identified by amino acid and position number  in  the RSV PR followed by the  substituted  amino acid (italicized). Amino acids 
are denoted by the  single  letter code. Deletion  mutations  are  indicated by A followed by the position  number of the  first  and  last  deleted  amino  acid. 
Multiple  amino  acid  substitutions are  indicated by the commas. 
* Oligodeoxynucleotides used  to place mutations  into  the pPR plasmid by site-directed  mutagenesis. 
New restriction  enzvme  sites  (underlined)  were  introduced  to  facilitate  identification f mutated clones. 
Indicates  the  loss OF the  original NcoI restriction  site. 
binding pocket (H65G, R105P, and G106V) and produced mu- 
tant  PRs  with expanded substrate specificity (10, ll). Amutant 
RSV PR containing all  three  substitutions  was capable of rec- 
ognizing a HIV-1 pol polyprotein cleavage site 50-fold more 
efficiently than  the wild type RSV PR. However, the  catalytic 
efficiency on other HIV-1 cleavage site substrates was un- 
changed. Subsequent  analysis of the activity of this  mutant on 
a library of peptide substrates containing single amino acid 
substitutions  in  the P4-P3' positions showed that  the HIV-1 
PR-like  behavior of this  mutant PR could be observed exclu- 
sively with P1- and P1'-modified peptide substrates (10). This 
suggested that  subsites of the  substrate binding pocket acted 
independently  in  the selection of substrate (9). In  this  report, 
we describe the expression,  purification, and  characterization 
of mutant RSV PRs  with  single  amino acid substitutions  in  the 
other  subsites of the  substrate binding pocket. The  results of 
this  analysis confirm our  earlier work and identify specificity 
determinants  in  subsites S2, S2', and S4. In  addition, we have 
identified amino acid residues within the substrate binding 
pocket which contribute to the differences in  catalytic efficiency 
of the RSV and HIV-1 PRs. 
EXPERIMENTAL PROCEDURES 
Bacterial Cells and DNA Constructs-Construction of the wild type 
RSV PR  and  NC-PR  expression  vectors  was  described  previously  (10). 
Escherichia coli MC 1061  cells  transformed  with  the  temperature-sen- 
sitive A-cI repressor  plasmid,  pRK248cIts,  were  used  for  the  expression 
of the  mutant  PR  proteins. 
Mutagenesis-Standard  site-directed  mutagenesis and oligode- 
oxynucleotide purification procedures were used to introduce amino 
acid changes  (substitutions  and/or  deletions)  into  the  protease coding 
region of the  plasmids  pPR or pNC-PR (10).  The  PR  mutations, oligode- 
oxynucleotides used in the mutagenesis reaction, and the diagnostic 
restriction  enzyme  sites  are  shown  in  Table  I.  Each  construct  was first 
verified by digesting  the DNA with  the  respective  diagnostic  restriction 
enzyme  and  later by sequencing. 
To construct  the  PR mutants  I4W; I44V; Q63M, M73V; 
M73VJi100L; V104T; S107N; N6lP,P62L,Q63M, A(61-63); V104T, 
R105P,G106V,S107N the  appropriate  purified oligodeoxynucleotide 
was  annealed  to  linearized (PuuI) and  gapped  (BglII-BssHII) DNAfrom 
wild type  PR. To construct  the  PR R105P,G106V,S107N mutant,  the 
oligodeoxynucleotide was  annealed to  purified  linear  (PvuI)  and  gapped 
(BgZII-BssHII) DNA from  PR R105P,G106V. NC-PR R105P,G106V was 
constructed by annealing  the  purified oligodeoxynucleotide to purified 
and linearized  (PvuI)  and  gapped (BgZII-BssHII) DNA from the wild 
type NC-PR construct. 
The  polymerase  chain  reaction  was  used  to  construct  PR H65G. The 
designated  purified oligodeoxynucleotides were  annealed  to wild type 
PR DNA, and VENT DNA polymerase  was  used  to  amplifiy  the DNA. 
The  amplified DNA fragment  was  then  digested  with  BglII  and EcoRI 
and the DNA purified. The 0.48-kb BgZII-EcoRI fragment was then 
ligated to  the purified 2.7-kb DNA fragment from wild type  PR  to yield 
PR H65G. 
PR R105P,G106V was produced by ligating  the  purified 0.48-kb Bg- 
ZII-EcoRI fragment from PR  to  the 2.7-kb DNA fragment  from NC-PR 
R105P,G106V. PR AlOOL was produced by ligating  the 0.55-kb MseI- 
AccI fragment from the aberrant PR M73VA100L construct to the 
2.5-kb dephosphorylated PflMI-AccI fragment and the 96-base pair 
PflMI-MseI fragments  from wild type  PR. 
Preparation of Retroviral Proteases-Wild type  and  mutant  proteins 
were  prepared  from E. coli grown in LB medium at pH  6.8  and  induced 
for  expression of RSV PR as described  previously (11). Cells  harvested 
and  washed by centrifugation  were  suspended in  10 m~ Tris.HC1, pH  8.0, 
in Y10 the  culture volume and  disrupted  with EDTA (10 m ~ )  and ly- 
sozyme (1 mg/ml) followed by treatment  with  Triton X-100 (1%). The 
pellet  was collected and  washed by sequential  suspension  and  centrifu- 
gation  (four  times),  first  with 25% sucrose, 1% Triton X-100 and  then 
with  sucrose/Wton X-100 containing  4 M and  then 6 M urea.  The  inclu- 
sion bodies were solubilized in 8 M urea  and  150 m~ 2-mercaptoethanol, 
and  the  protease  was refolded by dialysis ( 0 . 5 1  mg of proteidml) at 
23 "C against a decreasing  concentration of urea  (4,  2,  and 1 M for 2  h 
each).  The  final  dialysis  (against  25 m~ sodium  phosphate,  pH 7.5, 150 
m~ NaCl, and  10 m~ 2-mercaptoethanol)  was  overnight.  The  clarified 
soluble  fraction  containing  active  PR  was  stored at  4 "C. The  prepara- 
tions  were at least 95% pure as determined by sodium dodecyl sulfate- 
polyacrylamide  gel  electrophoresis  with Coomassie staining  (12).  Pro- 
tein  concentrations  were  determined  using  the Bio-Rad protein  assay kit 
and bovine serum  albumin as a standard.  In some  experiments, wild type 
and  mutant PR  subunits  were mixed in 8 M urea  and  renatured  together. 
AIvW PR,  purified from virus as described (13),  was  obtained from 
Molecular  Genetic  Resources,  Tampa,  FL. HIV-1 PR  expressed in  and 
purified from bacteria  was a generous  gift of Dr. Joe  Giam,  Case West- 
ern Reserve  University. 
Peptides-The peptides  were  synthesized and purified as described 
previously (6). Peptides were solubilized in 1 m~ 2-mercaptoethanol, 
and  their  concentrations  were  determined by quantitative  amino acid 
composition analysis. Specificity of cleavage  was  established by direct 
amino-terminal  analysis of product  peptides  (6). 
Assay of PR Actiuity-The reaction  mixture  contained 100 m~ so- 
dium phosphate, pH 5.9, 2.4 M sodium chloride, 100 p~ peptide, and 
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the AMVl'RSV NC-PR substrate, 
FIG. 1. Schematic representation of 
PAVSLAMT from P4 to P4' in the S4 
to 54' subsites of PR. The  relative  size 
of each  subsite  is  illustrated by the  area 
enclosed by the curved  line  around  each 
substrate side chain. Protease residues 
forming the  subsites  are  shown for those 
that differ between the AMV/RSV and 
HIV-1 PRs.  The AMV/RSV PR  residue  is 
shown  outside of the  parentheses,  and  the 
HIV-1 PR  residue  is  shown  in  the  paren- 
theses. Most of the  residues  contribute to 
more than one adjacent  subsite,  and  this 
is  indicated by the position of the label. 
\ I \  
50-500 rm active PR. Reaction volumes were 25 pl. Reactions were 
initiated by the  addition of PR,  incubated for various  periods of time, 
and  stopped by the addition of 300  pl of 0.5 M sodium  borate,  pH  8.5. 
Twenty pl of 0.05% (wh)  fluorescamine  was then added. HIV-1 PR  was 
never  incubated  more  than 8 min  because of its instability,  presumably 
a  result of autodegradation.  After  reaction  with  fluorescamine,  the  rela- 
tive fluorescence was  determined on a  Perkin-Elmer LS-50B spectroflu- 
orometer  using an excitation  wavelength of 386  nm  and an  emission 
wavelength of 477 nm. Excitation  and  emission  slit  widths  were 5 and 
10 nm, respectively. Relative fluorescence intensity was converted to 
nmol of product using a standard curve described by the following 
equation: nmol of product = relative fluorescence intensity/313. The 
standard curve was obtained using a hexapeptide with a free amino 
terminus (11). The concentration of this peptide was determined by 
amino acid composition analysis.  The  peptides  used  in  this  study  were 
designed  with  prolines at  their  amino  termini so that  the  relative fluo- 
rescence intensity represents only the newly formed amino termini 
produced as a result of proteolytic  cleavage.  Each  activity  measurement 
reported represents the mean of at  least three independent experi- 
ments. In each case, the standard error for all experiments did not 
exceed 20% of the  value  reported. 
Determination of Efficiency of Refolding PR-PR, 50-500 nM, (E,) 
was incubated in a reaction mixture containing 100 p~ NC-PR and 
between 0 and 500 nM inhibitor  peptide (PPCV-PheSta-AMTM) as  de- 
scribed above. The PPCV-PheSta-AMTM peptide is, in our hands, a 
5-20 nM inhibitor of PR,  depending  upon  the  enzyme  used.  The velocity 
(V) of each  reaction  was  plotted as a function of the concentration of 
inhibitor.  The  data  were  then fit to  the following equation  described by 
Cha  (14)  using  the  program  GraFit  (Erithacus  Software  Limited). 
0.5((F[Et1 + [I,i + $)' - 4F[Et1[Iti))'/" 
(Eq. 1) 
where k is  the  initial velocity of the reaction in  the absence of inhibitor, 
F is the fraction folded, I, is the  inhibitor  concentration,  and K, is the 
inhibition  constant.  Both F and K, were allowed to vary. 
Molecular Modeling-The crystal  structures of the  native RSV PR 
(15) and HIV-1 PR, as  well as  the complexes of the  latter with inhibitors 
(1C20) were  superimposed  using C, atoms  and  examined on an  Evans 
and  Sutherland ESVlO computer  graphics  system  using  the  program 
FRODO (21).  The  residues  forming  the  subsites  were  determined di- 
rectly for the HIV-1 PR complexed with  inhibitors,  and  the  correspond- 
ing  residues  in RSV PR  were  obtained from the  structural  and  sequence 
alignments (10). The NC-PR  substrate  was modeled as  described  pre- 
viously (101, and  different  amino acid side  chains  were  substituted at 
positions  P4  to  P3' of the  substrate  and  at  the  mutations  in RSV PR  to 




Rationale for Mutations in  the RSV PR-The ability to de- 
sign RSV PRs  with partial HIV-1 PR specificity by changing 
only nonconserved amino  acids  in the  S1  and S1' subsites (10, 
11) suggested that a complete change  to HIV-1 PR specificity 
might be achieved by identification and  simultaneous replace- 
ment of all key amino acid residues  in  the five additional RSV 
PR subsites. To identify these  residues, a detailed  structural 
and kinetic analysis of subsites of RSV and HIV-1 PRs was 
conducted (9). A list of potential  amino  acids that could influ- 
ence substrate specificity is provided in Table I and includes 
His-65, Arg-105, Gly-106, Ile-42, Ile-44, Gln-63, Met-73, Ala- 
100, Val-104, and Ser-107. The  subsites  to which each residue 
has been assigned are indicated in Fig. 1. In each case, the 
amino acid found in the structurally analogous position of 
HIV-1 PR was placed into RSV PR by site-directed mutagenesis 
of the appropriate expression plasmid. Several mutant PRs 
were constructed which contained  multiple substitutions. Also 
presented  in Table I is the description of a mutation  that de- 
letes  residues  61-63 from RSV PR. These residues  are  part of 
the long RSV PR flaps, and  their removal is predicted to pro- 
duce flaps of the  same  length as those of HIV-1 PR (10). In 
addition,  our modeling suggested that  these <extra" residues of 
RSV PR could potentially  influence substrate  interactions  in 
the  S4,  S3,  and S3'  subsites. 
Effect of Amino  Acid  Substitutions  on the Activity of Mutant 
PRs-The activity of each RSV mutant  with  the wild type RSV 
NC-PR peptide substrate is presented  in Table 11. The  activity 
data  have been corrected for efficiency of protein refolding by 
active site  titration of the enzymes using a nM peptide inhibitor 
as described under "Experimental Procedures." With the excep- 
tion of the I42D mutant,  all of the recombinant  PRs refolded 
with  similar efficiencies, although  the degree of folding varied 
between 18 to 30% from preparation  to  preparation.  The I42D 
protein tended  to form a precipitate upon refolding. Many of the 
amino acid substitutions produced enzymes with specific ac- 
tivities  greater  than wild type RSV PR (Table 11). Exceptions 
were the I42D, M73V, and A100L. Structural  data suggested 
that  the side chains of Met-73 and Ala-100 (Val-56 and Leu-76 
in HIV-1 PR) could form intramolecular  van  der Waal's inter- 
actions. If this  interaction is important for catalytic activity, 
Mutational  Analysis of Enzyme 
TABLE I1 
Activity of RSVproteases  with  mutations in the substrate 
binding pocket 
~ ~~ 
PR mutation Activity” 
min” 









M73V, AlOOL 11.4 
V104T 29.8 
S107N 49.0 





dures” using mutated RSV PRs as indicated and the RSV  NC-PR pep- 
., Activity was determined as described  under “Experimental Proce- 
tide substrate. See Table I for explanation of italics and commas. 
then  substitution of one of these amino  acids  in the absence of 
the  other  is expected to produce PRs with low activity. This 
appears to be the case,  since a double mutant containing  both 
M73V and AlOOL substitutions  is almost as active as wild type 
(Table 11). 
Of the  mutant RSV PRs  tested, those  with substitutions a t  
63  and 107 were the most active; each resulted  in at  least a 
4-fold increase  in specific activity. The  triple  mutant 
N6lP,P62L,Q63M also produced a more active enzyme. How- 
ever, its specific activity was no greater  than  that observed with 
the Q63M substitution alone. This  suggests  that  the increased 
activity of the  triple  mutant PR may be attributed  primarily to 
the  substitution at position 63. Increased  activity  was  also ob- 
served  when substitutions were placed a t  positions 44 and  104 
and when residues 61-63 were  deleted (see Table 11). 
Substitutions at residues  105  and 106 had previously been 
shown not to change the activity of the  mutant PR (10). How- 
ever, when the  amino acid substitution at  107 was combined 
with those at 105 and 106, a 7-fold increase  in specific activity 
was observed. However, combination of the substitutions at 
104,105,106,  and 107 produced an enzyme that  was only 4-fold 
more  active than wild type. Thus,  the effects of single muta- 
tions on the  rate of cleavage are  not necessarily  additive. 
Activity of Mutant  RSV  PRs on Modified NC-PR Peptide 
Substrates-Each of the above mutants was examined for 
changes  in  substrate preference using  the  library of NC-PR 
peptides  with  amino acid substitutions  in  the  P4  to P3’ sub- 
strate positions. This  set of peptides  detects differences in  the 
specificities of HIV-1 and RSV PRs(9, lo), and those  analyzed 
here revealed large differences in activity in the two PRs. 
Among the  mutations  that increased the specific activity of the 
RSV PR,  substitutions at positions 104  and 107 did  not cause 
detectable changes  in  substrate preference. For instance,  the 
V104T or the S107N mutation  is predicted to influence the S1 
and S1’ subsites. Yet, there  was no detectable  change in activity 
of these  mutants toward P1-substituted NC-PR peptide  sub- 
strates  as  might be expected for increased HIV-1-like behavior 
(Fig. 2, E and F ) .  This  is  in  contrast to observations  with the 
R105P,G106V substitutions  using  the  same modified NC-PR 
substrates (10). When the V104T or S107N mutant  was  tested 
with NC-PR substrates  that contained amino acid changes in 
other peptide positions, there were no new substrate prefer- 
ences  noted  (Fig. 2, A and D ) .  
In  contrast  to enzyme subsite  substitutions at  residues 104 
and 107, substitution of residues 42 and 44 does induce  changes 
in  substrate preference. Both residues have been assigned to 
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the  S2  and  S2’  subsites (9), and  residue 42 is also near  the  S4 
subsite (see Fig. 1). We tested each of these RSV mutants with 
substrates  that change  both  valine in  P2 (Fig. 2C)  and  alanine 
in  P2’  to leucine, a hydrophobic amino acid with  a larger side 
chain (Fig. 2 0 ) .  With the leucine  P2 NC-PR peptide,  both the 
42 and  the 44 enzyme substitution exhibited HIV-1-like speci- 
ficity. However, with the leucine P2’ NC-PR peptide, only the 
I44V substitution behaved  like HIV-1 PR. Similar HIV-1-like 
specificity was observed with the NC-PR peptide substrate con- 
taining  serine  and glycine in  P2  and  alanine  in P2’ (data not 
shown). Although changes in specificity were detected with 
peptides  with  changes in positions P2  and P2‘, none was ob- 
served  with  changes at P3’, Pl’, and  P3  (data not  shown), P1 
(Fig.  2, E and F ) ,  or P4 (Fig. 2, A and B ) .  
The I42D mutant showed increased  activity  toward a peptide 
containing histidine in the  P4 position (Fig. 2A ). This  increase 
was not observed when the  charge or size of the side  chain at 
this position was  changed by insertion of asparagine (Fig. 2B) 
or glycine (data not shown). This suggests that  the increase 
observed with  histidine  is  the  result of a local ionic interaction 
between Asp-42 in  the PR and  histidine  in  the  substrate. 
Of the  other  mutants  tested, only the A61-63 deletion mu- 
tant appeared to induce HIV-1-like preference for substrate 
amino  acids in  the  P4 position of the NC-PR peptide (see Fig. 2, 
A and  B).  The  mutant  that  contains N6lP,P62L,Q63M  did  not 
exhibit altered specificity even  though the specific activity of 
this enzyme relative to wild type was increased. Thus, the 
removal of residues 61-63 appears to be the  important factor in 
changing  substrate preference in  the  S4 enzyme subsite. As is 
the case for mutations at  42 and 44 and  the S2 and  S2‘  subsites, 
the A6143 mutation appears to affect only the S4 subsite. 
Changes in  substrate preference were not observed with 
NC-PR peptides altered at P2 or P2’ (Fig. 2, B and C )  or in  the 
other positions (data not shown). 
Activity of PR Mutants on Substrates Representing H W  
Cleavage Sites-A series of peptide substrates  that  represent 
five of the nine cleavage sites  in HIV-1 gag andpol polyproteins 
were  used as  substrates for the  mutant RSV enzymes (Table 
111). The I44V mutant had a significantly increased rate of 
cleavage of the HIV-1 CA-NCb (Fig. 3B) and RT-IN (Fig. 3E) 
peptide substrates. The I420 mutant had increased activity 
toward the RT-IN (Fig. 3E) and NC-p6b (Fig. 3B) substrates.  In 
the  latter case, the HIV-1 NC-p6b substrate was cleaved a t  a 
rate comparable to  that observed with the wild type HIV-1 PR. 
The A61-63 mutant increased the PR cleavage of the CA-NCb 
peptide substrate (Fig. 2 B ) ,  whereas  the double mutant 
M73V,A100L showed increased  activity on the RT-IN substrate 
(Fig. 3 0 ) .  The  other  mutants listed in Table I1 exhibited only 
marginal changes in activity toward these HIV-1 substrates 
(Fig. 3) .  In every case  in which there was  significant activity, 
the  site of cleavage was established by amino-terminal  analysis 
of product  peptides and shown to be the  same  as with HIV-1 PR. 
Several mutants, including the I44V, A61-63, and S107N, 
showed small increases  in activity  toward the CA-NCa and/or 
the NC-p6a peptides  (Fig. 2, A and C).  None of these  mutations 
affected cleavage of  RSV peptide substrates  (data  not shown). 
This  is consistent with  the fact that  the HIV-1 PR can cleave 
eight of the  nine RSV peptide substrates (6). 
DISCUSSION 
Cleavage site specificities of the RSV and HIV-1 PRs are very 
broad. In  their respective gag and gag-pol polyproteins, each 
efficiently cleaves in vivo nine different  sequences (I). To un- 
derstand  the molecular basis for this specificity, we have ana- 
lyzed each of the RSV and HIV-1 PR substrate binding pockets 
by substituting  structurally analogous  amino  acids of HIV-1 PR 
into the RSV PR. This has allowed us to identify RSV PR 
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FIG. 2. Protease  activities  with NC-PR peptide  substrates  substituted  at  the P4,  P2,  P1, and P2' positions. The NC-PR substrate 
(PPAVS-LA"RR) was modified with single amino  acid substitutions in  the positions indicated, and the activity with purified AMV PR, HlV-1 
PR, and RSV mutant PRs (as described in Table 11) was assayed as described under "Experimental Procedures." The data  are expressed as activity 
with modified substrates relative to  that observed with the wild type (WT)  NC-PR peptide substrate. The following modified NC-PR peptide 
substrates were  used: P[HlAVS-VA"RR (panel A), P[NlAVS-VAMTMRR (panel   B) ,  PPNLIS-VADITMRR (panel C ) ,  PPAVS-L[LIFRR 
(panel   D),  PPSWWI-LA"RR (panel E ) ,  and PPAV[Ll-LAMTMRR (panel F ) .  The dashed line indicates the protease cleavage site. The 
bracketed  letter denotes the amino  acid that  has been  changed  from the wild type  sequence. The nonbold letters are amino acids not present in the 
polyproteins. 
residues  42,44,65, 73, 100, 105, and 106 as those that  dictate when peptide-like inhibitors are employed as antivirals (9). 
differences in specificity relative to HIV-1 PR (see Fig. 1). We This prediction has recently been verified by the isolation of 
have found that  the deletion of residues 61-63 also  influences drug-resistant  variants  with  mutations at Val-82 (221, Val-32, 
substrate selection in  the  S4 subsite. By analogy, the respective and G l ~ - 4 8 . ~  
structurally related residues, 30,32,  48,56, 76, 81, and 82, in The combined structural and molecular genetic approaches 
HIV-1 PR must play an  important role in  substrate recognition. used in  these  studies  have confirmed that,  to a large extent, 
This  has led to  the prediction that  these amino  acids would  be 
those that rapidly mutate to form resistant enzymes in vivo R. Swanstrom and J. Kay, personal communication. 
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TABLE 111 
Peptides used as  PR substrates 
Virus and location of cleavage site Peptide sequence" 
RSV 
gag NC-PR 
gag CA-NCa PARVL-AEAMRR 
gag CA-NCb PATIM-MQRERR 
gag NC-p6a PGNF-LQSRR 
pol RT-IN PRKIL-FLDGRR 
HN- 1 
PPAVS-LAMTMRR 
gag NC-p6b PRQAN-FLGKRR 
Hyphens indicate the scissile bond.  In addition to the P4-P3' amino 
acids assumed to interact with the PR, amino-terminal prolines were 
added to avoid reactivity with fluorescamine and carboxyl-terminal 
arginines to improve solubility. 
individual  enzyme subsites  act independently in accommodat- 
ing  an amino acid side chain from a  corresponding substrate 
position. As has been suggested earlier (9, 11, 25),  the overall 
choice of substrate  is dictated by the  sum of all of the enzyme 
subsites.  Thus,  the  relative independence of subsites provides a 
mechanism for accommodation of the wide variety of sequences 
present in retroviral polyprotein cleavage sites. Despite this 
independence,  most of these critical residues in the PRs con- 
tribute  to more than one subsite,  and  substrates with large or 
bulky  side chains show effects that depend upon adjacent  resi- 
dues.  For  example, Tozser et al. (23)  have described steric ef- 
fects between residues in the P1' and P2 peptide substrate 
positions for the HIV-1 PR. For an  analysis of the  characteris- 
tics of each  enzyme subsite, see  Cameron et al. (9). 
The  nature of the  interactions between amino  acids in  the 
substrate binding pockets and those in  the  substrate  appears to 
involve mainly  side chain  van  der Waal's forces. This  is best 
illustrated  with  the  substitution of I44V in  the RSV S2 subsite 
(see Fig. 4). The NC-PR peptide substrate  contains valine in  the 
P2 position whose side  chain is predicted to form an intermo- 
lecular van der Waal's interaction with Ile-44 of PR. If the 
enzyme's isoleucine is changed to valine, as  in HIV-1 PR,  the 
potential  to form optimized van  der Waal's interactions  is lost, 
resulting  in a significant  decrease in activity. Wild type activity 
can be restored by substituting leucine for valine,  presumably 
by adding  the lost  methylene  group,  critical for van  der Waal's 
interactions, to the amino acid side chain in P2 position of 
substrate (Fig. 4). 
Other examples of enhanced hydrophobic interactions  with 
amino acid side chains in the substrate and enzyme can be 
found with RSV PR  residues 73 and 100, and with deletion of 
residues 61-63. The former are  present  in  the  S2  and  S2'  sub- 
sites,  and  the  latter  are  unique  to  the RSV PR and form part of 
the  S4  subsite lying near  the enzyme  surface. The  extra amino 
acids, 61-63, can explain why more nonpolar residues  can be 
accommodated in  the  P4 position of substrate by the RSV PR 
than by the HIV-1 PR (9). 
Although  optimization of van  der Waal's interactions  appears 
to be extremely important for substrate selection in  all of the 
subsites, ionic or H bond interactions  are also possible at some 
positions. This is  illustrated by the  14W  mutant, which shows 
a preference for a basic residue  in  the  P4 position of the NC-PR 
substrate (Fig.  3). 
In exchanging  amino  acids from comparable structural posi- 
tions of HIV-1 and RSV PRs, we have also  identified residues 
that influence the  rate of catalysis of the enzyme. These  include 
both amino acids that influence the selection of substrate,  such 
as Ile-42 and Ile-44, and deletion of residues 61-63, as well as 
those that do not,  such as Val-104 and Ser-107. Val-104 and 
Ser-107 are involved in  interactions  that  maintain  the  struc- 
tural  integrity of the PR catalytic site. In HIV-1 PR, Thr-80  is 
the  residue analogous to Val-104 in RSV PR. Structural  anal- 
ysis  shows that  Thr-80 forms a hydrogen bond interaction with 
the carbonyl oxygen of Val-82. Thus  the V104T mutant  is pre- 
dicted to introduce a similar interaction between the threonine 
hydroxyl and  the carbonyl oxygen of Gly-106. This  is predicted 
to increase the  stability of the second JI loop structure  in  the 
RSV PR which could lead to a higher catalytic rate. A similar 
argument  can be made for the S107N mutation,  in  that  Am-83 
in HIV-1 PR can form hydrogen bond interactions with the 
amide of Glu-34 and  the carbonyl oxygen of Glu-21. The effect 
on the  rate caused by mutation  and deletion of residues 6 1 4 3  
is more difficult to interpret since this region is  not visible in 
the  crystal  structure of the RSV PR because of disorder. How- 
ever, these  residues were modeled as an  insertion  in  the flap of 
RSV PR compared with  that  in HIV PR (10). Thus,  their  re- 
moval is expected to produce RSV flaps of the  same  length  as 
those in HIV-1 PR. The increased rates of catalysis for the 
mutations  that delete or alter  these  residues  in RSV PR sug- 
gest  that  the  shorter flaps of HIV PR are more favorable for 
product  release. In  general, we have found that  mutations  that 
affect the  rate of cleavage are those that  alter PR structural 
architecture,  whereas those that influence substrate selectivity 
alter  van  der Waal's interactions between the side chains of 
amino  acids in  the  substrate  and enzyme. 
The fact that HIV-1 PR has a more rigid  active site  structure 
than the RSV PR suggests that the HIV-1 PR may be less 
dependent upon substrate side chain  interactions for activity. 
For instance, the HIV-1 PR tolerates glycine substituted in 
each of the NC-PR substrate positions, whereas RSV  PR does 
not (9). This may also  explain why the HIV-1 PR has a  broader 
substrate specificity than  the RSV PR and  can cleave heterolo- 
gous RSV polyprotein substrates (6). 
The notion that  the specificity is determined by the  sum of 
contributions from individual subsites implies that  within a 
given substrate not all amino acid positions will contribute 
equally to  the  interaction with the  retroviral PRs. This may 
explain variations  in  the activity of the RSV PR mutants with 
the HIV-1 peptide substrates (Fig. 3). The substitution I44V 
results  in a considerable  increase in activity  toward two of the 
HIV-1 polyprotein substrates, RT-IN and CA-NCb, but only 
modest increases  in activity  toward the  three  other  substrates 
tested.  In a similar fashion, the  14W  mutant showed increases 
only with the NC-p6b and RT-IN substrates  and  the A61-63 
mutant only with the CA-NCb peptide. The combination mu- 
tant M73V,A100L also showed activity  toward the HIV-1 CA- 
NCb peptide substrate. This latter  result indicates that  these 2 
residues  are also important for substrate selection, probably 
because of their contributions to  the S2 and S2' enzyme sub- 
sites. However, this assignment is based only on structural 
data since the  mutant  has not been analyzed  with the modified 
NC-PR peptides. 
A closer examination of the amino acid sequences of the 
HIV-1 cleavage peptides  (see Table 111) provides an explanation 
for the observed enzyme  preferences. The RSV I44V mutant 
acts more effectively on the two HIV-1 substrates  that contain 
isoleucine in  the  P2 position. Thus,  the  enhancement  in activity 
can be related to improved van der Waal's interactions between 
isoleucine in  P2  and Val-44 in  the PR, as  illustrated  in Fig. 4. 
The RSV 14W prefers HIV-1 substrates  that contain basic resi- 
dues in the  P4 position. This is consistent  with the  data  in Fig. 
W, which show increased  activity of the  14W  mutant toward a 
NC-PR peptide substrate containing histidine  in  the  P4 posi- 
tion. The  presence of histidine at  P4 of the RSV NC-PR peptide 
improves the binding  affinity for enzyme by about 2-fold (9). 
The  activity of the RSV I42D mutant toward the NC-p6b sub- 
strate is equal or better  than  that seen  with the wild type HIV-1 
PR. This  is consistent  with the fact the NC-p6b substrate con- 
tains  arginine  in  P4  and lysine  in P4', yielding potential ionic 
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FIG. 3. Protease activities with HlV-1 peptide substrates. Peptide substrates representing HIV-1 polyprotein cleavage sites CA-NCa 
(PARVL-AEAMRR) (panel A),  CA-NCb (PATIM-MQRERR) (panel B ) ,  NC-p6a  (PGNF-LQSRR) (panel C ) ,  NC-p6b  (PRQAN-FLGKRR) (panel 
D ) ,  and RT-IN (PRKILFLDGRR) (panel E )  were incubated with mutant PR (as indicated)  and PR activity  determined as described under 
“Experimental  Procedures.”  The data are presented  as  relative  activity to cleavage of the RSV  NC-PR peptide substrate. The  sequence  notations 
are  the same as in the legend  to  Fig. 2. WT, wild  type. 
interactions  with both Asp-42 and Asp-42’. This  latter  inter- 
pretation implies that  in addition to  the seven enzyme subsites 
already defined (91, an  eighth subsite, S4’, also functions in 
substrate selection by interacting with the P4’ substrate posi- 
tion.  This has been confirmed in  separate  experiments  in which 
amino acid substitutions were placed into  the P4’ position of 
the NC-PR substrate  and found to alter cleavage of these  sub- 
strates by RSV PR (data not shown). 
Of the various subsites of the PR,  S2 appears  to  have  the 
greatest influence on substrate selection. This  can be explained 
by considering two features.  First, S2 (and S2’) is compara- 
tively small,  and  the size of the amino acid that  can bind  easily 
is  restricted. Second, as described by Gustchina et al. (24), P2 
differs from other positions, including P2’, in forming two rela- 
tively strong hydrogen bond interactions between its amide and 
carbonyl oxygen, the flap, and  the conserved water molecule. 
This predominance of the S2 subsite  can be seen  in  the HIV-1 
peptide cleavage data presented in Fig. 3. Furthermore, differ- 
ences between HIV-1 and HIV-2 PRs could be attributed to 
Val-32 and Ile-47, respectively, in  the S2 subsites (231, whereas 
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FIG. 4. Side chain interactions between the RSV residue 44 in 
the 52 subsite with the P2 position of the NC-PR substrate. The 
van  der Waal’s interaction  between RSV PR residue  44  and  substrate 
residue  P2  in  the model structure  is  shown  in  a  dot-surface  represen- 
tation.  The  side  chains of the modeled residues  have  been  rotated  to 
give a good fit,  the Ile-44 in  the  crystal  structure  was  not moved. Panel 
A, wild type RSV protease  Ile-44 from the  crystal  structure  with  valine 
in  the P2 position of the NC-PR sequence.  Panel B,  RSV PR mutant 
containing  the I44V substitution  and  valine  in  the  P2 position of the 
NC-PR substrate. Panel C ,  RSV PR  mutant  with the I44V substitution 
and  leucine  in  the  P2 position of the NC-PR substrate. Note that  these 
illustrations  are from the model without  energy  minimization. In prac- 
tice there would probably be some rearrangement of the  protein  and 
peptide  structure  to accommodate these  residues. However, as  this fig- 
ure  shows,  any  rearrangement  to  improve  the  contact for the Val-44 
with  the  valine a t  P2,  panel B,  would have  to involve changes  in  the 
position of the  main  chain  atoms  and  is likely to be more unfavorable 
than simply  rotating  the  side  chain. 
differences between equine infectious anemia  virus  and HIV-1 
PR were attributed to D30T and Z50V changes also in  the S2 
subsite. 
The small size of the retroviral PR, its broad substrate speci- 
ficity, the relative ease at  which it can be genetically manipu- 
lated  and assayed  with  peptide substrates,  and  the availability 
of structural  data  make  this  an ideal model system for studying 
protein-protein  interactions. Understanding  the molecular ba- 
sis of substrate selection for this system  should provide infor- 
mation applicable to more complex  biological problems includ- 
ing antibody interaction with an  antigen  and  other cell surface 
components of the  immune system. 
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